ETM
BIIB icon

Euclidean Technologies Management’s Biogen BIIB Stock Holding History

Euclidean Technologies Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-739
Closed -$256K – 85
2021
Q2 		$256K Buy
+739
New +$224K 0.2% 60
2020
Q4 		– Sell
-7,860
Closed -$2.23M – 56
2020
Q3 		$2.23M Hold
7,860
– – 2.81% 3
2020
Q2 		$2.1M Hold
7,860
– – 2.95% 3
2020
Q1 		$2.49M Hold
7,860
– – 4.1% 2
2019
Q4 		$2.33M Buy
+7,860
New +$2.18M 2.42% 3

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Euclidean Technologies Management's BIIB Position: Q3 2021 in Review

Euclidean Technologies Management sold out of Biogen (BIIB) in Q3 2021, closing a stake of 739 shares — an estimated $256K sold.

Euclidean Technologies Management first reported a position in BIIB in Q4 2019 and held it in 5 quarters. The position peaked at $2.49M in Q1 2020. 1,041 funds tracked by Wall St. Rank hold BIIB as of Q3 2021.

  • Euclidean Technologies Management reported no remaining Biogen position as of Q3 2021 after selling out during the quarter.
  • Euclidean Technologies Management sold 739 Biogen shares in Q3 2021, an estimated $256K.
  • Euclidean Technologies Management first reported a position in Biogen in Q4 2019 and held it in 5 quarters.
  • Euclidean Technologies Management's Biogen position peaked at $2.49M in Q1 2020.
  • 1,041 funds tracked by Wall St. Rank held Biogen as of Q3 2021.

Based on Euclidean Technologies Management's 13F filing for Q3 2021, filed 2 Nov 2021.